Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Medivir Ab

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Other

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Suzhou Suncediabiopharmaeuticals Co., Ltd.

Jiangsu Hengrui Co., Ltd.

Unitris Biopharma Co., Ltd.

Piaoyang Sun

Lianshan Zhang

Qing Dong

Weikang Tao

Qiyue Hu

Yongjiang Chen

Fei Li

Guaili Wu

Guoqing Cao

Hejun Lu

Xiangdong Qu

Dongbing Cui

Lingjia Shen

Xin Ye

Guangliang Yu

Kaihong Yuan

Shaoyu Xu

Bin Gui

Feng He

Jiong Lan

Bertil Samuelsson

Fanglong Yang

Hans Kristian Wallberg

Tony Johnson

Hongjian Jiang

Xiaohui Gao

Yayuan Fu

Mingxun He

Jiahua Jiang

Jiajian Liu

Hongbo Fei

Zhuoxiao Cao

Yuxia Wu

Kevin Parkes

Fangfang Jin

Ming-Hua Xu

Guo-Qiang Lin

Houcong Jin

Xin-Sheng Lei

Haowei Wang

Xing Liu

Lei Zhang

Wei He

Bin Wang

Jie Li

Yang Chen

Yang Wayne Wang

Ling L Zhang

Tao Liu

Peng Cho Tang

Yun Lu

Yali Wang

Jianbiao Peng

Zhen Yan

Jijun Yuan

Changan Sun

Fuyao Zhang

Changyong Yang

Yan Fang

Guangyuan Shen

Quanliang Zhang

Cheng Liao

Jiang Fan

Pingping Wang

Wei Peng

Lei Chen

Jindong Liang

Bonian Liu

Xiaotao Li

Baohai Yang

Hengli Yuan

Bo Yuan

Kai Pan

Zhibin Xu

Chunfei Wang

Xiaoming Shen

Changshan Guo

Chunzhou Han

Chunqian Fang

Gaoqiang Hu

Lin Shen

Jing Gao

Jifang Gong

Xinsheng Lei

Yunshu Zhou

Bei Yuan

Aifeng Lv

Chunyong Hu

Binqiang Feng

Xianbo Liu

Jianjun Zou

Chunyan Gu

Xin Li

Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.

LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof

The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.

PD-L1 antibody, antigen-binding fragment thereof and medical application thereof

An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R&#x3b1; polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.

Interleukin 15 protein complex and use thereof

A combination of a VEGFR inhibitor and a PARP inhibitor is described. In particular, this combination can be used in the preparation of a medicament for treating gastric cancer.

Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer

Interleukin 15 protein complex

A method for preventing or treating tumor diseases with a combination of a tyrosine kinase inhibitor and a CDK4/6 inhibitor is provided. In particular, a method for preventing or treating tumor diseases, including administering to a patient a tyrosine kinase inhibitor of a compound of formula (I), or a complex, a pharmaceutically acceptable salt or a stereoisomer thereof and a CDK4/6 inhibitor is provided. 

Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor

The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.

PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof

A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.

Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine

Pharmaceutical uses of pyridinecarboxamide derivatives are provided. In particular, pharmaceutical uses of pyridinecarboxamide derivatives represented by general formula (I), wherein the substituents of the formula (I) are defined in the specification, are provided. The pyridinecarboxamide derivatives can be used as therapeutic agents, especially as inhibitors of the Renal Outer Medullary Potassium channel (ROMK) and in the preparation of medicaments for treating and/or preventing ROMK mediated disorders, such as hypertension and heart failure. 

Pharmaceutical uses of pyridine carboxamide derivatives

Pyrazolopyrimidone derivatives and methods of use thereof are described. Specifically, pharmaceutical uses of pyrazolopyrimidone derivatives represented by the general formula (II) and pharmaceutically acceptable salts thereof are described, wherein the definitions of substituents in the general formula (II) are the same as the definitions in the specification. The pyrazolopyrimidone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis. 

Pyrazolopyrimidone derivatives and methods of use thereof

The present invention relates to an oxa spiro derivative, a preparation method therefor, and applications thereof in medicines. Particularly, the present invention relates to an oxa spiro derivative represented by formula (I), a preparation method therefor, and a pharmaceutical composition comprising the derivative, applications thereof as an MOR receptor agonist, and applications in the preparation of drugs for treating and/or preventing pains and pains-related diseases. Substituent groups in the formula (I) are same as definitions in the specification. 

Oxa spiro derivative, preparation method therefor, and applications thereof in medicines

Processes for preparing pyridinecarboxamide derivatives are provided. In particular, process for preparing pyridinecarboxamide derivatives represented by general formula (I) are provided, wherein the substituents of the formula (I) are defined in the specification. 

Processes for preparing pyridine carboxamide derivatives

The present invention relates to a benzopiperidine derivative, a preparation method thereof and a medical use thereof. In particular, the present invention relates to a benzopiperidine derivative as shown by general formula (I), a preparation method thereof and a pharmaceutical composition containing the derivative, as well as a use thereof as an estrogen receptor modulator in the prevention and/or treatment of estrogen receptor-mediated or dependent diseases or conditions. Preferably, the disease is breast cancer. The substituents in the general formula (I) are the same as those defined in the description. 

Benzopiperidine derivative, preparation method thereof and medical use thereof

Growing community of inventors

Jiangsu, China

Piaoyang Sun